Overview

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term multiple sclerosis (MS) outcomes in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Biogen
Treatments:
Interferon beta-1a
Interferon-beta
Interferons